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LAY SUMMARY
Yttrium-90 trans-arterial radioembolization (TARE) is a microembolic procedure that minimizes alterations of the hepatic arterial flow, and thus can be safely performed also in patients with hepatocellular carcinoma (HCC) and tumoral portal vein invasion (PVTT). In this study, we retrospectively evaluated the independent predictors of long-term outcomes in patients with HCC and PVTT treated with TARE. Bilirubin level, extension of PVTT and tumor burden were independently related to post-treatment survival: the combination of these factors allowed us to build a prognostic stratification that may help to better identify good candidates for the treatment, and those for whom TARE may be futile.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a global health problem and one of the leading causes of cancer-related death especially in cirrhotic patients (1, 2) . By reason of the improvements in surveillance protocols, diagnostic tools and therapeutic armamentaria, diagnosis of early HCC is feasible in 30-60% of cases (3) . However, a substantial proportion of patients still present tumoral portal vein thrombosis (PVTT) either at onset of the disease or as result of HCC recurrence or progression, leading to an advanced stage of the disease not amenable to curative treatments (4) .
Patients with HCC and PVTT may present asymptomatic although in most instances have a significant degree of synthetic dysfunction and an impending liver decompensation that precludes any attempt of surgical cure. Moreover, when the portal circulation is compromised by thrombosis, trans-arterial embolo-therapies may increase the risk of liver failure; therefore, the presence of PVTT is generally considered as a contraindication to trans-arterial chemoembolization (TACE). (5, 6) Two pivotal phase III trials have demonstrated a survival advantage for patients with advanced HCC treated with the oral multi-tyrosine kinase inhibitor sorafenib (7, 8) with respect to placebo, and a subgroup analysis has confirmed this result also in patients with PVTT (9, 10) . Sorafenib has been therefore recognized as the standard of care for the treatment of advanced HCC by the American Association for the Study of Liver Diseases (AASLD) (11) , the European Association for the Study of the Liver (EASL)(5) and the Asian Pacific Association for the Study of the Liver (APASL) (12) . Nevertheless, sustained responses to sorafenib are rare, median survival in patients with advanced HCC remains limited to 6.5 -10.7 months, and the treatment itself is associated with side effects that frequently lead to early treatment interruption (7, 8, 13, 14) .
Trans-arterial radioembolization (TARE) is a form of brachyterapy performed by selective intraarterial injection of microspheres loaded with Yttrium-90 (Y 90 ): a pure beta-emitter characterized by limited penetration, that enables selective tumor treatment with limited damage of the surrounding tissue (15) . Unlike other trans-arterial therapies, TARE is a microembolic procedure that minimizes alterations of the hepatic arterial flow (16) : several large series on TARE for patients with HCC and PVTT, mostly restrospective, showed an acceptable safety profile and good results in terms of local control of the disease (17) (18) (19) (20) (21) . Only recently, two phase III randomized clinical trials (RCT) comparing TARE to the standard of care sorafenib in the population of patients with locally advanced HCC, have been made accessible (22) , (23) . In both trials the primary endpoint was not met, since TARE did not provide a significant gain in survival compared to sorafenib in the overall population nor in the subgroup of patients with PVTT. Incidentally, both studies clearly showed a significantly better treatment tolerance and quality of life in patients undergoing TARE.
Aim of this study is to identify, in a prospectively collected series of patients with PVTT treated with TARE, the prognostic factors with relevant impact on patients' survival (overall survival, OS), in order to build a prognostic classification that may allow to identify patients who would benefit most from the treatment. Approval for the study was obtained from the local Institutional Review Board.
METHODS

This is
Pre-treatment staging
Pre-treatment patients' assessment and tumor staging were performed the day before 99Tc-macroaggregated albumin ( 
Treatment and dosimetry
Informed consent was obtained from all subjects before every angiographic procedure. TARE was performed in two sessions, as previously described (21) 
Follow-up
After TARE, patients were followed-up on an outpatient basis at months 1, 3, 6 and then every four months by means of contrast-enhanced thoraco-abdominal CT scan, physical examination and laboratory analysis including AFP. Adjunctive visits or hospitalizations were added whenever required depending on patients' or physicians' request and on detectable changes in clinical conditions.
Liver decompensation (LD) was defined as the occurrence of any of the following: clinically detectable ascites, bleeding from esophageal varices, hepatic encephalopathy, total bilirubin >3 mg/dL, and prothrombin time international normalized ratio >2.2 (21) . Tumor progression was assessed according to RECIST criteria 1.1. The variations of PVTT extension during follow-up
were not considered in tumor response evaluation. All CT scans were independently revised by two experienced radiologists (CSpr, MV); whenever evaluation was not overt, agreement was reached with a third radiologist on staff.
At progression, patients were treated according to disease presentation after multidisciplinary discussion. In particular, patients with a maintained liver function and an intrahepatic progression amenable to locoregional treatments were offered repeated TARE or percutaneous ablation;
patients with a maintained liver function not amenable to locoregional treatments were offered sorafenib; patient presenting with liver decompensation were offered best supportive care.
Statistical analysis
Categorical variables were reported as the number of cases and percentages; continuous variables were expressed as median and interquartile range (IQR). Overall survival, progressionfree survival (PFS) and time to liver decompensation were estimated by the Kaplan-Meier method, and calculated from the date of TARE. Survival curves were compared by the log-rank test. Median follow-up was calculated with the reverse Kaplan Meier method.
For the survival analysis, continuous variables were transformed into qualitative or ordinal variables according to ranges of normality for laboratory values, clinical relevance or the median value of the given parameter. The event of interest was death for any cause: univariate analysis was performed for all the variables under study, and then multivariable analysis using the Cox proportional-hazards model was used to explore the variables that showed an independent relationship with survival. The proportionality assumption was verified by Schoenfeld residual analysis. A prognostic score was then derived using the independent variables weighed according to the estimated β regression coefficient of the final Cox model. The risk estimate associated with each point was then calculated using the Cox proportional hazards model. Three prognostic categories were identified according to the changes in the risk estimates for each point increase of the score. The OS curves, PFS curves and risk of liver decompensation were then obtained with the Kaplan-Meier method and compared by means of log-rank test.
All analyses were 2-tailed and the threshold of significance was assessed at p<0.05. The statistical analysis was performed using IBM® SPSS® Statistics, version 20. 10.7-17.5), and 1yr and 3yrs-OS were 53.2% and 18.5% respectively (Figure 1, panel A) . Median PFS was 6.5 months (95%CI: 3.8-9.2), and 1yr and 3yrs progression-free survival (PFS) were 35.2% and 0% respectively (Figure 1, panel B) . The rate of liver decompensation (LD) was 10.8%
RESULTS
at 3 months and 31.6% at 6 months.
No patients in the present series underwent subsequent resection. Only one patient (with PVT type 1) underwent liver transplant (LT) after showing a sustained complete response 1 year after TARE.
He is alive and well after 24 months but his follow-up for this study was censored at the time of LT.
The first site of tumor progression was intra-hepatic in 59 patients (76.6% of progressions): 
Development of the prognostic classification
The results of the univariate analysis on baseline patients characteristics are presented in Table 2 .
Those variables identified as significant at univariate analysis were fitted in a multivariable Cox proportional hazards regression model: the only variables independently correlated with survival were bilirubin, PVTT grade and tumor burden at the time of TARE; the proportionality of hazard ratios for all levels of all prognostic factors was verified. The beta coefficients were transformed into relative points as shown in Figure 2 . The hazard function identified a clear-cut change in the hazard ratio at the sum of 2 points and > 3 points. Thus, three prognostic categories were identified: favourable prognosis (0 points), intermediate prognosis (2-3 points) and dismal prognosis (> 3 points). Median OS in the three categories was 32.2 months, 14.9 months and 7.8 months respectively (p<.0001, Figure 2 ). Also PFS (p=.045) and risk of liver decompensation (p<.0001) were significantly stratified according to the three proposed prognostic categories, as reported in Table 3 . Median PFS was 14.1 months (with a 42.1% 3-years OS) in patients with normal bilirubin, limited tumor burden and PVT limited to segmental branches (favourable prognostic group); conversely TARE in patients with more than one risk factor (> 3 points) yielded a median PFS of 4.1 months, a risk of liver decompensation of 21.6% at 3 months and no survivors at 3 years. In Figure 3 , three cases of patients with HCC and different grades of PVTT (type 1, 2 and 3 respectively) are showed before and after TARE treatment.
DISCUSSION
Despite consistent advancements in the clinical management of HCC, the therapeutic options for patients with locally advanced disease because of PVTT are very limited.
Radioembolization with Y 90 has been recognized as a safe and effective treatment for unresectable HCC, as acknowledged in several guidelines (5, 11, 29) . In several non-comparative studies (17) (18) (19) (20) (21) 30 ) published in the last decade on patients with HCC and PVTT, treatment with TARE has demonstrated an excellent safety profile, with median OS ranging from 10 to 13 months. These survival outcomes appeared superior to those obtained with sorafenib (7, 8) and this has fuelled retrospective comparative studies (31, 32) and two randomized clinical trials comparing TARE and sorafenib in the setting of locally advanced HCC. All these studies -although not specifically focused on the subset of patients with PVTT -failed to confirm a meaningful survival benefit provided by TARE with Y 90 microsphere (22, 23) .
In this study we report the long term outcomes of a consecutive series of patients with HCC and PVTT treated with TARE. As shown in Figure 1 , median and 3-years OS were 14.1 months and 18.5% respectively. Overall, these results are superior than those previously reported by our group (21) , and amongst the best reported in literature for patients offered such treatment outside clinical trials: this is probably related to the stringent application of refined selection criteria, derived from our previous experience. In fact, in the present series, patient with PVTT were treated with TARE only in presence of compensated liver function (within Child-Pugh A-B7 stage) and with no occlusion of the main portal trunk. This resulted also in a 0% treatment-related mortality, and in an acceptable rate of liver decompensation at 3 months of 10.8%.
Considering the resource impact of TARE in the current practice of HCC treatment, the main endpoint of our study was to identify the independent prognostic factors for OS in patients with HCC and PVTT treated with TARE and to assess whether or not different prognostic categories could correlate with predictable patient outcomes in advanced HCC maintaining sufficient liver function. At multivariable analysis, only 3 variables (PVTT extension, tumor burden in terms of liver volume replacement and baseline serum total bilirubin) were found to have an independent impact on post-treatment survival.
The extension of PVTT is known to directly affect patients prognosis: with respect to segmental invasion, thrombosis of more proximal branches increases the risk of tumor spread, and induces elevation of portal venous pressure causing higher risk of variceal hemorrhage, ascites, and liver failure (33) . The influence of PVTT extension on post-treatment outcomes has been demonstrated in several series of HCC patients treated with TARE (21, 33, 34) , but also in patients treated by means of radical surgical resection (35) . To be noted, patients with main PVTT were not treated at our Center. Based on the available literature (15, 17, 21) TARE in this setting provides a median OS from 3 to 6 months, not seeming to provide a meaningful survival benefit. This is probably due to the fact that main PVTT is vascularized by arterial feedings coming from the common hepatic artery, and thus and thus out of reach for microspheres injected when performing lobar or selective treatments (through first or second order arterial branches).
Tumoral burden replacing > 50% of total liver volume also independently affected survival. Not Bilirubin was the only liver-related factor that showed an independent correlation with posttreatment survival. Again, this was relatively expected because the study population was relatively homogeneous in terms of liver function, being 97.2% of patients in Child-Pugh A and having an ALBI grade <3 in 99.2% of cases. Baseline bilirubin levels showed an independent influence on survival in other series of patients treated with TARE (19, 20) : higher bilirubin at baseline is a sign of liver dysfunction and a predisposing factor for post-treatment bilirubin toxicity, which is a common adverse event after TARE, particularly in patients with PVTT (17) .
A distinctive feature of this study is the development of a prognostic score derived from the estimated β regression coefficients of the final Cox model for extension of PVTT, tumor burden and serum bilirubin values at the time of treatment. According to the changes in risk estimates three prognostic categories were thus identified, that allowed a significant prognostic stratification in terms of OS, PFS and risk of liver decompensation at 3 months as shown in Figure 2 and Table 3 .
In particular, patients with 0 points (absence of adverse prognostic factors) were those with a favourable prognosis. These patients showed a median OS of 32.2 months and a median PFS of 14.1 months, with a negligible risk of TARE-related liver decompensation (3.2 % after 3 months).
The favourable prognosis subgroup achieved in fact a remarkable survival outcome that is comparable to unresectable HCC undergoing trans-arterial chemoembolization in the absence of PVTT (36, 37) . This result indirectly suggests that HCC patients with segmental PVTT and good liver function may be considered a sub-category of the intermediate stage HCC according to the BCLC classification (38) . Thus, besides confirming that TARE may be considered as the first line treatment in such a patients' subgroup, the observed median PFS of 14.1 months may well justify consideration of TARE as a down-staging treatment to liver transplantation in selected patients with segmental PVTT.
Patients expressing one of the aforementioned prognostic factors (2-3 points) can be considered a subgroup at intermediate prognosis. In this category of patients TARE works with a palliative purpose, even though the observed median OS of 14.9 months remains definitively higher than what expected with a first line systemic therapy. Considering the good tolerability of the treatment, and the acceptable risk of liver decompensation at 3 months (less than 10%), in field practice TARE can be proposed as a reasonable alternative to systemic treatments when the composite assessment of post-TARE prognosis turns out to be in the intermediate-risk category (Figure 2 ).
According to the results of our prospective series, patients expressing more than one of the prognostic factors should be considered at a dismal prognosis. In this category median OS was 7.8 months, therefore with a much inferior benefit than what expected with systemic therapy.
Considering also a risk of liver decompensation of 21.6% at 3 months, TARE for this patients' subgroup may be futile and potentially harmful, and thus should be avoided.
Our study has some limitations. Tumor or PVT absorbed doses were not specifically evaluated. Table 1 . Baseline characteristics of the study population Table 2 . Uni-and multivariable analysis on overall survival of 120 patients with PVTT-associated HCC receiving trans-arterial radioembolization (TARE) as elective treatment 
TABLES LEGEND
HIGHLIGHTS
• A prognostic score for post-TARE survival in patients with HCC and PVTT is proposed
• Bilirubin, PVTT extension and tumor burden were independently related to survival
• The combination of these factors allowed identifying three prognostic categories
• The proposed prognostic categorization may allow better treatment allocation 
